Е. А. Smolyarchuk

4.8k total citations
37 papers, 224 citations indexed

About

Е. А. Smolyarchuk is a scholar working on Molecular Biology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Е. А. Smolyarchuk has authored 37 papers receiving a total of 224 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Infectious Diseases and 6 papers in Epidemiology. Recurrent topics in Е. А. Smolyarchuk's work include Neurological Disorders and Treatments (4 papers), COVID-19 Clinical Research Studies (3 papers) and Influenza Virus Research Studies (2 papers). Е. А. Smolyarchuk is often cited by papers focused on Neurological Disorders and Treatments (4 papers), COVID-19 Clinical Research Studies (3 papers) and Influenza Virus Research Studies (2 papers). Е. А. Smolyarchuk collaborates with scholars based in Russia, United States and Australia. Е. А. Smolyarchuk's co-authors include Vladimir N. Chubarev, Susanna S. Sologova, С. Б. Фитилев, Artem P. Tkachuk, Daria V. Vasina, Gintsburg Al, Vladimir Chulanov, Vladimir А. Gushchin, Ruitai Fan and Edmund C. M. Tse and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Molecular Sciences and Annals of the Rheumatic Diseases.

In The Last Decade

Е. А. Smolyarchuk

25 papers receiving 207 citations

Peers

Countries citing papers authored by Е. А. Smolyarchuk

Since Specialization

Citations

This map shows the geographic impact of Е. А. Smolyarchuk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Е. А. Smolyarchuk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Е. А. Smolyarchuk more than expected).

Fields of papers citing papers by Е. А. Smolyarchuk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Е. А. Smolyarchuk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Е. А. Smolyarchuk. The network helps show where Е. А. Smolyarchuk may publish in the future.

Co-authorship network of co-authors of Е. А. Smolyarchuk

This figure shows the co-authorship network connecting the top 25 collaborators of Е. А. Smolyarchuk. A scholar is included among the top collaborators of Е. А. Smolyarchuk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Е. А. Smolyarchuk. Е. А. Smolyarchuk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Analysis of the Main Directions in the Development of Mono and Combination Pharmacotherapy Acting on Hormonal Signaling Pathways of Breast Cancer According to the FDA Databases and Clinicaltrials.gov 2025 ·Current Medicinal Chemistry ·(unknown), (unknown), (unknown), (unknown), Маргарита Е. Неганова, Junqi Liu, Samsonov MIu, А. В. Самородов, Е. А. Smolyarchuk, Olga Sukocheva, Vladimir N. Chubarev	3
2	Efficacy and safety of Aviandr in patients with anxiety disorders after coronavirus infection (COVID-19): interim results of a multicenter observational post-registration study 2025 ·(unknown), A B Danilov, B. A. Volel, (unknown), (unknown), Alexandre V. Ivachtchenko, (unknown), (unknown), (unknown), Е. А. Smolyarchuk, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), А. Е. Морозов, Vadim V. Tarasov	0
3	The parameters of long-term humoral immunity induced by a single injection of the Sputnik Light vaccine among non-infected volunteers and those infected with SARS-CoV-2 2025 ·PubMed ·Fatima M. Izhaeva, Amir I. Tukhvatulin, Alina S. Dzharullaeva, Inna V. Dolzhikova, Olga V. Zubkova, Dmitry V. Shcheblyakov, Nadezhda L. Lubenets, Е. А. Smolyarchuk, (unknown), Alina S. Erokhova, (unknown), (unknown), Olga Popova, (unknown), Boris S. Naroditsky, Denis Y. Logunov, Gintsburg Al	0
4	Metacognitive awareness of pharmacists at different stages of the educational continuum: a comparative study 2025 ·Frontiers in Education ·(unknown), (unknown), Susanna S. Sologova, (unknown), (unknown), (unknown), (unknown), Е. А. Smolyarchuk	0
5	Variants of rhinitis medicamentosa treatment: a systematic review 2025 ·European Archives of Oto-Rhino-Laryngology ·(unknown), (unknown), (unknown), (unknown), Е. А. Smolyarchuk, (unknown)	0
6	Analysis of Clinical Success and Molecular Mechanisms of Action of Novel Anti-glioblastoma Drugs: A Review 2024 ·Current Medicinal Chemistry ·(unknown), Vladimir N. Chubarev, (unknown), (unknown), Маргарита Е. Неганова, Е. А. Smolyarchuk, Junqi Liu, Olga Sukocheva, (unknown), R. N. Alyautdin	1
7	Regulatory Peptide Pro-Gly-Pro Accelerates Neuroregeneration of Primary Neuroglial Culture after Mechanical Injury in Scratch Test 2024 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Е. А. Smolyarchuk, (unknown), Л. А. Андреева, N. F. Myasoedov, Аndrey P. Fisenko, Kirill V. Savostyanov	1
8	Pharmaceutical Agents for Targeting Autophagy and Their Applications in Clinics 2024 ·Pharmaceuticals ·(unknown), Susanna S. Sologova, Е. А. Smolyarchuk, Vladimir Prassolov, Pavel Spirin	5
9	Unraveling the Mechanism of Platelet Aggregation Suppression by Thioterpenoids: Molecular Docking and In Vivo Antiaggregant Activity 2023 ·Biomimetics ·Л. Е. Никитина, (unknown), Alexander A. Ksenofontov, Е. В. Антина, (unknown), Roman S. Pavelyev, (unknown), (unknown), (unknown), (unknown), (unknown), С. А. Рубцова, Sergei Boichuk, Aigul Galembikova, Е. А. Smolyarchuk, И Г Мустафин, Airat R. Kayumov, А. В. Самородов	0
10	Metabolic effects of vasopressin in pathophysiology of diabetic kidney disease 2023 ·Frontiers in Endocrinology ·(unknown), (unknown), Е. А. Smolyarchuk, (unknown), (unknown), Alexander Tonevitsky, Kerim Mutig	4
11	Development of a Method and a Scheme for the Use of a Live Recombinant Vaccine "GamLPV". Safety and Tolerability of Double Intranasal Vaccination of Healthy Adult Volunteers 2022 ·Drug development & registration ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Л. В. Колобухина, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Е. А. Smolyarchuk, (unknown)	5
12	Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems 2022 ·Molecules ·(unknown), Vladimir N. Chubarev, (unknown), (unknown), В. А. Меркулов, Susanna S. Sologova, (unknown), Е. А. Smolyarchuk, R. N. Alyautdin	16
13	Choosing a Lecture Format in Higher Pharmaceutical Education 2022 ·Voprosy Obrazovaniya/ Educational Studies Moscow ·Tatiana Semenova, Susanna S. Sologova, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Е. А. Smolyarchuk	2
14	Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial 2022 ·Journal of Translational Medicine ·Е. Д. Баздырев, (unknown), (unknown), Е. А. Smolyarchuk, (unknown), (unknown), (unknown), Fedor N. Novikov	4
15	The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study 2021 ·Inflammation Research ·N. V. Lomakin, (unknown), Д. Н. Проценко, Mazurov Vi, (unknown), О. М. Моисеева, (unknown), Vladimir O. Popov, Е. А. Smolyarchuk, И. Г. Гордеев, Mikhail Gilyarov, Daria Fomina, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	35
16	Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study 2020 ·Vaccines ·Artem P. Tkachuk, (unknown), (unknown), (unknown), (unknown), Vladimir Chulanov, С. Б. Фитилев, (unknown), Е. А. Smolyarchuk, (unknown), Daria V. Vasina, Vladimir А. Gushchin, Gintsburg Al	49
17	Levosalbutamol and new opportunities for the treatment of bronchial asthma (review of the related studies) 2018 ·SHILAP Revista de lepidopterología ·(unknown), Е. А. Smolyarchuk	1
18	Possibilities of adaptive design implementation in clinical trials of next-in-class drugs 2018 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Е. А. Smolyarchuk, Andrey А. Svistunov	0
19	Biotechnological preparations as a means of improving the safety of pharmacotherapy: state of the art and prospects of development 2018 ·SHILAP Revista de lepidopterología ·(unknown), Е. А. Smolyarchuk, (unknown), Smirnov Vv, (unknown)	1
20	TELMISARTAN IN CARDIOVASCULAR RISK REDUCTION 2018 ·CARDIOVASCULAR THERAPY AND PREVENTION ·О. Д. Остроумова, А. И. Кочетков, Е. А. Smolyarchuk, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact